LBRX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- LB Pharmaceuticals presents new preclinical evidence supporting LB-102's dual-mode mechanism of action and highlights its ongoing late-stage clinical programs at the 39th ECNP CongressOct 10, 2026
- LB Pharmaceuticals accelerates topline data timeline for the Phase 3 NOVA-2 schizophrenia trialJul 22, 2026
- LB Pharmaceuticals announced publication of Phase 2 NOVA-1 trial results for LB-102 in schizophrenia in JAMA PsychiatryApr 23, 2026
- LB Pharmaceuticals initiated the pivotal Phase 3 NOVA-2 trial of LB-102 for schizophreniaMar 25, 2026